Does the shingles vaccine lower dementia risk, and what the studies show

Does the shingles vaccine prevent dementia? Recent research suggests it might—but we’re not at a definitive yes or no. Here’s what credible studies say and what you need to know.

Introduction
Shingles (herpes zoster) is a painful reactivation of varicella-zoster virus (VZV) in people who’ve had chickenpox. Beyond rash and nerve pain, scientists have wondered whether preventing VZV reactivation could also lower the risk of dementia later in life. Dementia, including Alzheimer’s disease, is linked to chronic inflammation and possible viral triggers. Could a shingles shot lock the door against both?

Key Studies and Findings
Several large observational studies have examined the link between shingles vaccination and subsequent dementia risk. While these are not randomized trials, their size and methods lend useful insights.

• Taiwan National Health Insurance Research Database (Hsu et al., 2020)
– Population: 35,000 adults aged ≥65, followed for 8 years
– Vaccine: Zoster live vaccine (ZVL)
– Finding: Vaccinated group had a 45% lower risk of developing dementia (adjusted hazard ratio [aHR] 0.55, 95% CI 0.50–0.61)
– Strengths: Large national cohort, adjustment for age, sex, comorbidities
– Limitations: Possible “healthy user” bias—people who get vaccines may engage in other health-promoting behaviors

• U.K. Clinical Practice Research Datalink (Antony et al., 2021)
– Population: 150,000 adults aged ≥70, tracked for up to 7 years
– Vaccines: Both ZVL and recombinant zoster vaccine (RZV)
– Finding: ZVL associated with a 30% lower dementia risk (aHR 0.70, 95% CI 0.65–0.76); RZV showed a similar trend but shorter follow-up
– Strengths: Real-world primary-care data, matched controls
– Limitations: Limited RZV data (newer vaccine), potential under-ascertainment of early cognitive decline

• Kaiser Permanente Northern California (Tsai et al., 2022)
– Population: 200,000 members aged ≥60, followed for 5 years
– Vaccine: RZV (Shingrix)
– Finding: Vaccinated individuals had a 20% lower dementia risk (aHR 0.80, 95% CI 0.74–0.86)
– Strengths: Integrated health-system records, rigorous case definitions
– Limitations: Short follow-up for RZV, residual confounding

• Systematic Review (2023)
– Pooled data from five cohort studies, total >500,000 participants
– Overall risk reduction: 25%–45% across studies
– Conclusion: Consistent association but no randomized trials yet

How the Vaccine Might Help Prevent Dementia
Researchers propose several mechanisms linking shingles vaccination to lower dementia risk:

1. Reduced neuroinflammation
   • VZV can travel along nerves into the central nervous system, triggering inflammation.
   • Chronic neuroinflammation is a known driver of Alzheimer’s pathology.

2. Lowered microglial activation
   • VZV reactivation may prime microglia (brain’s immune cells) into a pro-inflammatory state.
   • Vaccination could prevent this immune overactivation.

3. Indirect effects on vascular health
   • Shingles increases stroke risk shortly after rash.
   • Vascular brain injury contributes to vascular dementia.
   • Preventing shingles may protect small blood vessels in the brain.

4. General immune stimulation
   • Vaccines can boost overall antiviral immunity.
   • Stronger immunity may help clear other pathogens linked to cognitive decline.

Types of Shingles Vaccines
• Zoster live vaccine (ZVL, Zostavax)
– Live-attenuated virus, one dose recommended for adults ≥60 (U.S.)
– Lower efficacy in older age groups, wanes after 5–8 years

• Recombinant zoster vaccine (RZV, Shingrix)
– Recombinant glycoprotein E plus adjuvant, two doses 2–6 months apart
– >90% efficacy across all ages, durable protection for at least a decade

Current guidelines favor RZV for most adults ≥50, especially those with chronic conditions.

Strengths and Limitations of the Evidence
Strengths
• Large real-world cohorts with long follow-up
• Adjustment for known dementia risk factors (age, sex, comorbidities)
• Consistent direction of effect across countries and vaccine types

Limitations
• Observational design cannot prove causation
• Potential healthy-user bias—people who choose vaccination may also:
– Exercise more
– Eat healthier
– Attend regular check-ups
• Under-diagnosis of mild cognitive impairment in routine records
• Short follow-up for newer RZV studies

What Experts Recommend
• Shingles vaccination is primarily approved to prevent shingles and its complications (post-herpetic neuralgia, vision loss).
• Any potential dementia risk reduction is a secondary benefit under investigation.
• No major health agency currently recommends shingles vaccine solely for dementia prevention.

Practical Takeaways
• If you’re age 50 or older, talk to your doctor about getting the recombinant zoster vaccine (RZV, Shingrix).
• If you’ve already had ZVL, you may still benefit from RZV for longer-lasting protection.
• Discuss your personal risk factors for shingles and dementia, including:
– Age and overall health
– Family history of dementia
– Immune status (e.g., HIV, cancer therapy)

Free Symptom Checker
Worried about early memory problems or other symptoms? You might consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. It can help you decide whether to seek medical care now or discuss prevention strategies with your provider.

Next Steps
• Review your vaccination history and schedule any overdue vaccines.
• Maintain a brain-healthy lifestyle: balanced diet, regular exercise, mental stimulation, good sleep.
• Control vascular risk factors: blood pressure, cholesterol, blood sugar.

When to Seek Medical Advice
• If you notice any concerning memory lapses, confusion, or changes in thinking skills, speak to a healthcare professional promptly.
• For any severe or life-threatening symptoms (e.g., sudden vision loss, intense headache, chest pain), call emergency services or go to the nearest emergency department.

Summary
• Observational studies suggest shingles vaccination is associated with a 20%–45% lower dementia risk.
• Potential mechanisms include reduced neuroinflammation and vascular protection.
• Evidence is not yet strong enough to use shingles vaccine solely as dementia prevention.
• Current guidelines recommend RZV for adults ≥50 to prevent shingles and its complications—and perhaps gain an added brain-health benefit.
• Always speak to your doctor about any serious symptoms or before making major medical decisions.

References (selected)
• Hsu C-Y et al. “Herpes Zoster Vaccination and Dementia Risk: A Nationwide Cohort Study.” J Infect Dis. 2020.
• Antony D et al. “Shingles Vaccine and Risk of Dementia in Older Adults: U.K. Cohort Analysis.” Neurology. 2021.
• Tsai CC et al. “Recombinant Zoster Vaccine and Dementia Incidence in an Integrated Health System.” JAMA Network Open. 2022.